As the number of antibody discovery platforms and formats expands, various characteristics must be rigorously screened for and taken into consideration when deciding which hits to progress to successful development. The earlier in the antibody discovery pathway the assessment is carried out, the greater the hit enrichment and selection will…
List view / Grid view
Issue #1 2018
Filter the results
High-throughput screening (HTS) has become an integral part of early stage drug discovery. This article looks at the use of the latest in vitro 3D cell and tissue culture model systems in HTS. We also highlight some of the bottlenecks and attempt a look into our crystal ball to identify…
There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.
The immune system is now regarded as a powerful weapon in the war against cancer, and in the current era immune cells have become ‘living drugs’. This review article considers some of the key advances in immuno-oncology...
As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
Next generation sequencing (NGS) has transformed biological research, invigorating the field of genomics, and has increased understanding of our genetic basis.
Efficient microplate readers play an important role in effective hit molecule discovery. Mark Wigglesworth, of AstraZeneca, explains what he looks for in this technology.
A look back, and forward, at the key trends within laboratory informatics.
High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative in vitro immunooncology screening platform
This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
Predictiveness is one of the key factors for success in the drug discovery workflow. Many compounds fail at late stages due to lack of predictive data or the discovery of unwanted side effects.